Short answer
MapLight Therapeutics, Inc. (MPLT) filed its Q3 2025 10-Q quarterly report on Dec 4, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$82M
- EPS (diluted)
- −$105.70
Source: XBRL data from the MapLight Therapeutics, Inc. (MPLT) Q3 2025 10-Q on SEC EDGAR. USD.
MapLight Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly added post-quarter IPO risk: $262.3 million net proceeds and 16,962,500 shares issued in October 2025
- Liquidity risk: accumulated deficit $281.0 million and continued operating losses requiring additional capital
- Regulatory risk: ML-007C-MA and ML-004 require Phase 2 trials and regulatory approval before commercialization
- Operational risk: dependence on third-party organizations for clinical development and trial execution
- Market risk: uncertain product acceptance and competition could prevent future revenue realization
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MapLight Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.